- Home
- CCM vs STTK Comparison
CCM vs STTK Comparison
Compare CCM & STTK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CCM
- STTK
- Stock Information
- Founded
- CCM 1997
- STTK 2016
- Country
- CCM China
- STTK United States
- Employees
- CCM N/A
- STTK N/A
- Industry
- CCM Medical/Nursing Services
- STTK Biotechnology: Pharmaceutical Preparations
- Sector
- CCM Health Care
- STTK Health Care
- Exchange
- CCM Nasdaq
- STTK Nasdaq
- Market Cap
- CCM 33.3M
- STTK 38.4M
- IPO Year
- CCM 2009
- STTK 2020
- Fundamental
- Price
- CCM $5.25
- STTK $0.85
- Analyst Decision
- CCM
- STTK Hold
- Analyst Count
- CCM 0
- STTK 4
- Target Price
- CCM N/A
- STTK $3.00
- AVG Volume (30 Days)
- CCM 16.4K
- STTK 506.8K
- Earning Date
- CCM 04-25-2025
- STTK 08-04-2025
- Dividend Yield
- CCM N/A
- STTK N/A
- EPS Growth
- CCM N/A
- STTK N/A
- EPS
- CCM N/A
- STTK N/A
- Revenue
- CCM $52,603,198.00
- STTK $4,606,000.00
- Revenue This Year
- CCM N/A
- STTK N/A
- Revenue Next Year
- CCM N/A
- STTK N/A
- P/E Ratio
- CCM N/A
- STTK N/A
- Revenue Growth
- CCM N/A
- STTK 69.65
- 52 Week Low
- CCM $3.80
- STTK $0.69
- 52 Week High
- CCM $10.77
- STTK $4.59
- Technical
- Relative Strength Index (RSI)
- CCM 40.52
- STTK 48.63
- Support Level
- CCM $5.04
- STTK $0.73
- Resistance Level
- CCM $6.85
- STTK $0.92
- Average True Range (ATR)
- CCM 0.82
- STTK 0.07
- MACD
- CCM 0.03
- STTK 0.01
- Stochastic Oscillator
- CCM 3.66
- STTK 61.81
About CCM Concord Medical Services Holdings Limited
Concord Medical Services Holdings Ltd operates radiotherapy and diagnostic imaging centers in China. The company is involved in the leasing of radiotherapy and diagnostic imaging equipment, provision of management services to hospitals, medicine sales, and provision of premium cancer and proton treatment services. The company has two operating segments, including network and hospital. Its network includes radiotherapy centers, diagnostic imaging centers, and centers providing other treatment and diagnostic services.
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.